Topiramate in migraine prophylaxis: Data from a pooled analysis and open-label extension study

G. Bussone, S. Usai, D. D'Amico

Research output: Contribution to journalArticle

Abstract

Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.

Original languageEnglish
JournalNeurological Sciences
Volume27
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Migraine Disorders
Double-Blind Method
Placebos
Maintenance
topiramate
Therapeutics

Keywords

  • Clinical trial
  • Migraine
  • Open-label extension phase
  • Pooled analysis
  • Prophylaxis
  • Topiramate

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Topiramate in migraine prophylaxis : Data from a pooled analysis and open-label extension study. / Bussone, G.; Usai, S.; D'Amico, D.

In: Neurological Sciences, Vol. 27, No. SUPPL. 2, 09.2006.

Research output: Contribution to journalArticle

@article{a42794b98c3948dd9c28b03abd5f6169,
title = "Topiramate in migraine prophylaxis: Data from a pooled analysis and open-label extension study",
abstract = "Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.",
keywords = "Clinical trial, Migraine, Open-label extension phase, Pooled analysis, Prophylaxis, Topiramate",
author = "G. Bussone and S. Usai and D. D'Amico",
year = "2006",
month = "9",
doi = "10.1007/s10072-006-0593-z",
language = "English",
volume = "27",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Topiramate in migraine prophylaxis

T2 - Data from a pooled analysis and open-label extension study

AU - Bussone, G.

AU - Usai, S.

AU - D'Amico, D.

PY - 2006/9

Y1 - 2006/9

N2 - Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.

AB - Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.

KW - Clinical trial

KW - Migraine

KW - Open-label extension phase

KW - Pooled analysis

KW - Prophylaxis

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=33746269166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746269166&partnerID=8YFLogxK

U2 - 10.1007/s10072-006-0593-z

DO - 10.1007/s10072-006-0593-z

M3 - Article

C2 - 16688622

AN - SCOPUS:33746269166

VL - 27

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 2

ER -